A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)
Details
Age
Adult
Locations
Cherry Creek Medical Center
Highlands Ranch Hospital
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Robert Lentz
Study ID
Protocol Number: 24-0927
More information available at ClinicalTrials.gov: NCT06109779
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers